Abstract

The Dana-Farber/Harvard Center for Medical Countermeasures against Radiation will use the Pilot Grant Program to promote innovative, cutting edge research in areas that may yield discoveries that would translate into the rapid creation of new medical countermeasures against radiation or nuclear exposure. The Pilot Grant Program will invest funds in research projects with the greatest potential to grow to full research programs or to projects that would be competitive for traditional NIH funding. The funds will be used to attract investigators from institutions and companies that are not participating in the DF/HCMCR network as well as investigators not currently working in the area of radiation countermeasures. Investigators will be encouraged to apply for Pilot Grant Project funding to expand their research plans. These Pilot Grant Program Funds will be used to encourage collaborations among investigators, particularly between basic and clinical research laboratories and between traditional radiobiology laboratories and investigators in other basic science disciplines (e.g. immunologists, cell biologists, chemical biologists, bioinformaticists). We are encouraging innovative thinking and expedited discovery through the development pilot projects in the area of response radiation exposure. Resulting in new and immediately applicable medical and therapeutic response to radiation exposure.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI067751-01
Application #
7054554
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Project Start
2005-09-01
Project End
2010-07-31
Budget Start
2005-09-01
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$130,562
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Beemelmanns, Christine; Ramadhar, Timothy R; Kim, Ki Hyun et al. (2017) Macrotermycins A-D, Glycosylated Macrolactams from a Termite-Associated Amycolatopsis sp. M39. Org Lett 19:1000-1003
Guinan, Eva C; Palmer, Christine D; Mancuso, Christy J et al. (2014) Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. Innate Immun 20:697-711
Guinan, Eva C; Barbon, Christine M; Kalish, Leslie A et al. (2011) Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med 3:110ra118
Tolopko, Andrew N; Sullivan, John P; Erickson, Sean D et al. (2010) Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics 11:260
D'Andrea, Alan D (2010) Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362:1909-19
Parmar, Kalindi; Kim, Jungmin; Sykes, Stephen M et al. (2010) Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 28:1186-95
Parmar, Kalindi; D'Andrea, Alan; Niedernhofer, Laura J (2009) Mouse models of Fanconi anemia. Mutat Res 668:133-40
Sun, Yingli; Jiang, Xiaofeng; Xu, Ye et al. (2009) Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11:1376-82
Moldovan, George-Lucian; D'Andrea, Alan D (2009) FANCD2 hurdles the DNA interstrand crosslink. Cell 139:1222-4
Kim, Jung Min; Parmar, Kalindi; Huang, Min et al. (2009) Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-20

Showing the most recent 10 out of 19 publications